TESARO Inc (NASDAQ:TSRO) shares dropped 5.6% during trading on Thursday . The stock traded as low as $61.68 and last traded at $61.86. Approximately 2,198,300 shares changed hands during mid-day trading, an increase of 58% from the average daily volume of 1,392,000 shares. The stock had previously closed at $65.52.

TSRO has been the topic of several analyst reports. Robert W. Baird reaffirmed a “neutral” rating and issued a $125.00 target price on shares of TESARO in a research note on Monday, October 2nd. ValuEngine downgraded shares of TESARO from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. HC Wainwright initiated coverage on shares of TESARO in a research note on Thursday, October 12th. They issued a “buy” rating and a $158.00 target price on the stock. Zacks Investment Research downgraded shares of TESARO from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Finally, Barclays initiated coverage on shares of TESARO in a research note on Monday, October 23rd. They issued an “equal weight” rating and a $135.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. TESARO presently has an average rating of “Hold” and a consensus price target of $149.97.

The company has a market capitalization of $3,480.00, a price-to-earnings ratio of -7.58 and a beta of 1.51. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.35 and a current ratio of 4.73.

TESARO (NASDAQ:TSRO) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The firm had revenue of $142.77 million for the quarter, compared to analysts’ expectations of $130.57 million. During the same quarter in the previous year, the business posted ($1.72) EPS. The company’s quarterly revenue was up 740.3% on a year-over-year basis. analysts expect that TESARO Inc will post -8.19 earnings per share for the current year.

In other news, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the sale, the senior vice president now owns 8,101 shares in the company, valued at approximately $690,529.24. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 40.50% of the company’s stock.

A number of institutional investors have recently made changes to their positions in TSRO. Stephens Inc. AR boosted its stake in TESARO by 6.5% in the 2nd quarter. Stephens Inc. AR now owns 1,874 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 115 shares in the last quarter. Teachers Advisors LLC boosted its stake in TESARO by 6.4% in the 2nd quarter. Teachers Advisors LLC now owns 167,285 shares of the biopharmaceutical company’s stock worth $23,396,000 after purchasing an additional 10,060 shares in the last quarter. BlackRock Inc. boosted its stake in TESARO by 5.7% in the 2nd quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock worth $504,230,000 after purchasing an additional 195,590 shares in the last quarter. Amalgamated Bank boosted its stake in TESARO by 93.0% in the 2nd quarter. Amalgamated Bank now owns 6,763 shares of the biopharmaceutical company’s stock worth $946,000 after purchasing an additional 3,259 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its stake in TESARO by 209.0% in the 2nd quarter. New York State Common Retirement Fund now owns 104,497 shares of the biopharmaceutical company’s stock worth $14,615,000 after purchasing an additional 70,676 shares in the last quarter.

WARNING: “TESARO (TSRO) Stock Price Down 5.6%” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/tesaro-tsro-stock-price-down-5-6/1815135.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.